RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2011 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM) today announced that Gordana Kosutic, M.D. has resigned as Vice President, Clinical and Regulatory Affairs, to pursue another opportunity. The Company has initiated a formal search for a Chief Medical Officer and has named M. Scott Harris, M.D., a consultant with Tranzyme since June 2010, to act in this capacity until a permanent replacement is appointed. In addition, Philippa Charlton, M.D., Tranzyme's Medical Director, will assume the day-to-day responsibilities for clinical operations. Dr. Kosutic will remain with the Company until September 30.
